Cargando…

The tumor microenvironment and immune responses in prostate cancer patients

The landscape of cancer treatment has been transformed over the past decade by the success of immune-targeting therapies. However, despite sipuleucel-T being the first-ever approved vaccine for cancer and the first immunotherapy licensed for prostate cancer in 2010, immunotherapy has since seen limi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, J T W, Bryant, R J, Parkes, E E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345898/
https://www.ncbi.nlm.nih.gov/pubmed/34128831
http://dx.doi.org/10.1530/ERC-21-0149